Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 10.60
+0.20 (1.92%)
Sep 25, 2026, 5:29 PM CET
Xbrane Biopharma AB Market Cap
Xbrane Biopharma AB has a market cap or net worth of 218.42 million as of September 25, 2026. Its market cap has decreased by -67.61% in one year.
Market Cap
218.42M
Enterprise Value
232.63M
Revenue
83.30M
Ranking
n/a
PE Ratio
n/a
Stock Price
10.60
ChartMarket Cap Chart
Since February 3, 2016, Xbrane Biopharma AB's market cap has increased from 131.05M to 218.42M, an increase of 66.66%. That is a compound annual growth rate of 4.91%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 25, 2026 | 218.42M | 3.92% |
| Dec 30, 2025 | 210.17M | -14.54% |
| Dec 30, 2024 | 245.94M | -17.28% |
| Dec 29, 2023 | 297.31M | -86.83% |
| Dec 30, 2022 | 2.26B | -13.94% |
| Dec 30, 2021 | 2.62B | 58.03% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Cantargia AB | 362.97M |
| Intervacc AB | 326.50M |
| Sprint Bioscience AB | 321.82M |
| IRLAB Therapeutics AB | 271.85M |
| Isofol Medical AB | 257.03M |
| Elicera Therapeutics AB | 182.52M |
| Diamyd Medical AB | 161.49M |
| Initiator Pharma | 142.38M |